Efinopegdutide Clinical Trials (2026): 7 Studies for Non-alcoholic Fatty Liver Disease & Nonalcoholic Fatty Liver Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Efinopegdutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Non-alcoholic Fatty Liver Disease & Nonalcoholic Fatty Liver Disease) and 856 total planned enrollment. Most recent activity: NCT06465186 (Aug 2026).
Efinopegdutide clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | Total |
|---|---|---|---|
| P1 | 3 | 3 | |
| P2 | 1 | 3 | 4 |
Efinopegdutide clinical trials by indication
Non-alcoholic Fatty Liver Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06465186 | MK-6024-017 | P2 | active not recruiting | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) |
| NCT05877547 | NASH | P2 | completed | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) |
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06701305 | MK-6024-015 | P1 | completed | A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) |
| NCT06836037 | MK-6024 | P1 | completed | A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) |
Metabolic Dysfunction-Associated Steatotic Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06482112 | MASLD | P2 | completed | Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) |
Non-alcoholic Steatohepatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06052566 | MK-6024-014 | P1 | completed | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) |
Nonalcoholic Fatty Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04944992 | MK-6024 | P2 | completed | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) |
Efinopegdutide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MK-6024-017 | NCT06465186 | P2 | active not recruiting | Non-alcoholic Fatty Liver Disease | 80 | — |
| NASH | NCT05877547 | P2 | completed | Non-alcoholic Fatty Liver Disease | 381 | — |
| MASLD | NCT06482112 | P2 | completed | Metabolic Dysfunction-Associated Steatotic Liver Disease | 124 | — |
| MK-6024 | NCT04944992 | P2 | completed | Nonalcoholic Fatty Liver Disease | 145 | PMID 37355043 |
All Efinopegdutide trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06465186 | MK-6024-017 | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | P2 | active not recruiting | 80 | Merck Sharp & Dohme LLC | Jul 2024 |
| NCT05877547 | NASH | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | P2 | completed | 381 | Merck Sharp & Dohme LLC | Jun 2023 |
| NCT06482112 | MASLD | Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | P2 | completed | 124 | Merck Sharp & Dohme LLC | Jul 2024 |
| NCT06701305 | MK-6024-015 | A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) | P1 | completed | 48 | Merck Sharp & Dohme LLC | Jun 2024 |
| NCT06052566 | MK-6024-014 | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) | P1 | completed | 22 | Merck Sharp & Dohme LLC | Nov 2023 |
| NCT06836037 | MK-6024 | A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) | P1 | completed | 56 | Merck Sharp & Dohme LLC | Sep 2022 |
| NCT04944992 | MK-6024 | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | P2 | completed | 145 | Merck Sharp & Dohme LLC | Aug 2021 |
Efinopegdutide clinical trials: frequently asked questions
- How many Efinopegdutide clinical trials are there?
- 7 Efinopegdutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are marked completed.
- Are Efinopegdutide clinical trials recruiting in 2026?
- No active Efinopegdutide trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Efinopegdutide being studied for?
- Efinopegdutide is being studied for Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Healthy and 7 more. The trials are grouped by indication on this page.
- What phase is Efinopegdutide in?
- Efinopegdutide clinical trials span 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Efinopegdutide clinical trials?
- The lead sponsor across the most Efinopegdutide trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Efinopegdutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: